<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>08437026887124</udiDi>
    <basicUdiDi>8437026887AD002YK</basicUdiDi>
    <tradeName>MAP-AD Test Software - Frontend</tradeName>
    <deviceName>MAP-AD Test Software</deviceName>
    <manufacturerName>ADmit Therapeutics</manufacturerName>
    <manufacturerSrn>ES-MF-000042518</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W02050192</emdnCode>
    <emdnDescription>NUCLEIC ACID TESTING INSTRUMENTS EXCEPT MICRO-ARRAYS - IVD MEDICAL DEVICE SOFTWARE</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>AD002</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:37:12.482Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437026887117</udiDi>
    <basicUdiDi>8437026887AD002YK</basicUdiDi>
    <tradeName>MAP-AD Test Software - Frontend</tradeName>
    <deviceName>MAP-AD Test Software</deviceName>
    <manufacturerName>ADmit Therapeutics</manufacturerName>
    <manufacturerSrn>ES-MF-000042518</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W02050192</emdnCode>
    <emdnDescription>NUCLEIC ACID TESTING INSTRUMENTS EXCEPT MICRO-ARRAYS - IVD MEDICAL DEVICE SOFTWARE</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>AD002</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:37:11.271Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437026887100</udiDi>
    <basicUdiDi>8437026887AD002YK</basicUdiDi>
    <tradeName>MAP-AD Test Software - Frontend</tradeName>
    <deviceName>MAP-AD Test Software</deviceName>
    <manufacturerName>ADmit Therapeutics</manufacturerName>
    <manufacturerSrn>ES-MF-000042518</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W02050192</emdnCode>
    <emdnDescription>NUCLEIC ACID TESTING INSTRUMENTS EXCEPT MICRO-ARRAYS - IVD MEDICAL DEVICE SOFTWARE</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>AD002</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:37:05.264Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437026887094</udiDi>
    <basicUdiDi>8437026887AD002YK</basicUdiDi>
    <tradeName>MAP-AD Test Software - Backend</tradeName>
    <deviceName>MAP-AD Test Software</deviceName>
    <manufacturerName>ADmit Therapeutics</manufacturerName>
    <manufacturerSrn>ES-MF-000042518</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W02050192</emdnCode>
    <emdnDescription>NUCLEIC ACID TESTING INSTRUMENTS EXCEPT MICRO-ARRAYS - IVD MEDICAL DEVICE SOFTWARE</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>AD002</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:37:04.074Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437026887049</udiDi>
    <basicUdiDi>8437026887AD001YH</basicUdiDi>
    <tradeName>MAP-AD Test Oligos - Oligo2-Rev</tradeName>
    <deviceName>MAP-AD Test Oligos</deviceName>
    <manufacturerName>ADmit Therapeutics</manufacturerName>
    <manufacturerSrn>ES-MF-000042518</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W0106010201</emdnCode>
    <emdnDescription>ALZHEIMER'S DISEASE</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>AD001-04</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:37:02.865Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437026887032</udiDi>
    <basicUdiDi>8437026887AD001YH</basicUdiDi>
    <tradeName>MAP-AD Test Oligos - Oligo2-Fw</tradeName>
    <deviceName>MAP-AD Test Oligos</deviceName>
    <manufacturerName>ADmit Therapeutics</manufacturerName>
    <manufacturerSrn>ES-MF-000042518</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W0106010201</emdnCode>
    <emdnDescription>ALZHEIMER'S DISEASE</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>AD001-03</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:37:01.667Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437026887025</udiDi>
    <basicUdiDi>8437026887AD001YH</basicUdiDi>
    <tradeName>MAP-AD Test Oligos - Oligo1-Rev</tradeName>
    <deviceName>MAP-AD Test Oligos</deviceName>
    <manufacturerName>ADmit Therapeutics</manufacturerName>
    <manufacturerSrn>ES-MF-000042518</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W0106010201</emdnCode>
    <emdnDescription>ALZHEIMER'S DISEASE</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>AD001-02</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:36:55.668Z</lastUpdated>
  </row>
  <row>
    <udiDi>08437026887018</udiDi>
    <basicUdiDi>8437026887AD001YH</basicUdiDi>
    <tradeName>MAP-AD Test Oligos - Oligo1-Fw</tradeName>
    <deviceName>MAP-AD Test Oligos</deviceName>
    <manufacturerName>ADmit Therapeutics</manufacturerName>
    <manufacturerSrn>ES-MF-000042518</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>IVD Sınıf C</riskClass>
    <legislation>IVDR 2017/746</legislation>
    <emdnCode>W0106010201</emdnCode>
    <emdnDescription>ALZHEIMER'S DISEASE</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>AD001-01</reference>
    <placedOnMarketCountry>Spain</placedOnMarketCountry>
    <lastUpdated>2026-06-30T12:36:54.466Z</lastUpdated>
  </row>
</eudamedExport>